Existing Guidance Documents | |
• Pharmaceutical Manufacturers of America (PhRMA) (United States): “PhRMA Principles on Interactions with Patient Organizations” [14]. | |
• Clinical Trials Transformation Initiative CTTI Recommendations (United States): “Effective Engagement with Patient Groups Around Clinical Trials” [15]. | |
• European Federation of Pharmaceutical Industries and Associations (Europe): “EFPIA Code of Practice on Relationships Between Pharmaceutical Companies and Patient Organisations” [16]. | |
• BioPontis Alliance for Rare Diseases (United States and Europe): “Integrating Rare Disease Patients into Pre-Clinical Therapy Development; Finding Our Way with Patient Input” [17]. | |
Published Literature | |
• McCoy MS, Carnoil M, Chockley K, Urwin JW, Emanuel EJ, Schmidt H: Conflicts of interest for patient-advocacy organizations. N Engl J Med 2017;376:880–5. |